Sustained secretion of anti ‐tumor necrosis factor α monoclonal antibody from ex vivo genetically engineered dermal tissue demonstrates therapeutic activity in mouse model of rheumatoid arthritis

ConclusionsThe results of the present study report microdermal tissues engineered to secrete active adalimumab as a proof of concept for sustained secretion of antibody from the novel ex vivo gene therapy TARGT platform. This technology may now be applied to a range of antibodies for the therapy of other diseases.

Source: The Journal of Gene Medicine - August 25, 2017 Category: Genetics & Stem Cells Authors: Inbal Zafir ‐Lavie, Reem Miari, Shay Sherbo, Simi Krispel, Osnat Tal, Atar Liran, Tamar Shatil, Felix Badinter, Haim Goltsman, Nir Shapir, Itai Benhar, Garry A. Neil, Amos Panet Tags: RESEARCH ARTICLE Source Type: research